glimepiride or glipizide

Glimepiride and glipizide are oral antidiabetic medications belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. These drugs function by stimulating the pancreatic beta cells to release insulin and by enhancing the body's sensitivity to insulin. Their core mechanism involves binding to specific sulfonylurea receptors (SUR1) on ATP-sensitive potassium (K_ATP) channels located on the pancreatic beta cell membrane. This binding leads to the closure of these channels, causing depolarization of the beta cell membrane. The subsequent influx of calcium ions through voltage-gated channels triggers the exocytosis and release of insulin. Both glimepiride and glipizide are administered orally as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Glimepiride was patented in 1979, and glipizide was approved for medical use in the United States in 1984.

Brand names

AmarylGlucotrolGlucotrol XL